Gerresheimer completed Centor sale and Jefferies kept target for Gerresheimer stock at EUR 26.80
Published on 10/09/2026 at 14:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS- Gerresheimer completed the Centor sale on October 1, 2026, with proceeds earmarked for debt reduction.
- Preliminary second-quarter 2026 adjusted EBITDA rose to EUR 102.0 million from EUR 67.0 million in the first quarter.
- Gerresheimer stock was EUR 28.79 at Lang & Schwarz on October 9, 2026, up 1.34 percent from EUR 28.41.
- Jefferies kept a Hold rating and a EUR 26.80 price target after the preliminary results.
Gerresheimer completed the sale of its US subsidiary Centor on October 1, 2026, while Jefferies kept a EUR 26.80 price target for Gerresheimer stock. The transaction covers part of a combined EUR 1.5 billion enterprise value and the proceeds are intended to reduce debt, according to EQS News.
Three milestones reshape the group
On August 27, 2026, preliminary first-quarter figures showed revenue of EUR 523 million, adjusted EBITDA of EUR 67 million and free cash flow of negative EUR 30 million, according to Investing.com. On September 30, 2026, preliminary second-quarter revenue reached EUR 578 million and adjusted EBITDA reached EUR 102 million, according to Gerresheimer. The October 1 Centor completion was the latest step, with the cash inflow designated for debt reduction.
What does the sale change?
The transaction gives Gerresheimer a direct balance-sheet lever. The combined enterprise value for Centor and Primary Packaging Plastics is EUR 1.5 billion, with Centor accounting for roughly half, and the remaining Primary Packaging Plastics sale is expected in the first half of 2027, according to EQS News. The debt issue remains material because Jefferies cited higher net debt and lower liquidity when it kept its Hold rating and EUR 26.80 target on September 30, 2026, as reported by FinanzNachrichten.
Recovery improves sequentially
In the second quarter of 2026, adjusted EBITDA increased from EUR 67 million in the first quarter to EUR 102 million, a calculated 52.24 percent quarter-on-quarter increase. Revenue rose from EUR 523 million to EUR 578 million over the same periods, while the adjusted EBITDA margin reached 17.60 percent in the second quarter, according to Gerresheimer. The comparison is constructive sequentially, but the company also reported lower revenue and adjusted EBITDA than in the second quarter of 2025.
November brings two reports
Gerresheimer's investor calendar lists the final first-half 2026 financial report for November 2026 and the third-quarter communication for November 2026. The next reporting cycle will therefore test whether the disposal proceeds and operational recovery translate into lower leverage and stronger earnings.
Stock trades above the analyst target
Gerresheimer was trading at EUR 28.79 at Lang & Schwarz on October 9, 2026 at 2:18 p.m. CEST, up 1.34 percent versus the prior close of EUR 28.41. The latest price is EUR 1.99 above Jefferies' EUR 26.80 target, keeping the market quote above the analyst reference despite the Hold rating. The further course of trading is shown by the continuously updated real-time quote of Gerresheimer stock.
Gerresheimer stock at a glance
- Company: Gerresheimer AG
- ISIN: DE000A0LD6E6
- WKN: A0LD6E
- Ticker: GXI
- Primary exchange: Frankfurt Stock Exchange
- Price Lang & Schwarz as of October 9, 2026, 2:18 p.m. CEST: EUR 28.79
- Change versus prior close: plus 1.34 percent
- Prior close Lang & Schwarz October 8, 2026: EUR 28.41
- Market capitalization: EUR 993.4 million as of October 9, 2026
- 52-week range: EUR 14.83-32.00 as of October 9, 2026
- Sector / Industry: Healthcare / Medical Instruments and Supplies
Market context: Market report DAX.
